Actively Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
Led by MediLink Therapeutics (Suzhou) Co., Ltd. · Updated on 2025-12-24
424
Participants Needed
15
Research Sites
162 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
CONDITIONS
Official Title
A Study of YL242 in Subjects With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Adequate organ and bone marrow function
- For Parts 1-3: Have an advanced, unresectable, or metastatic solid malignant tumor and have received at least one prior systemic anti-tumor therapy
- For Part 4: Have locally advanced or metastatic non-squamous non-small cell lung cancer without AGA and HCC and have not received systemic anti-tumor therapy
- For Part 5: Have metastatic colorectal cancer and have received at least one prior systemic anti-tumor therapy
- For Part 6: Have advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer and have received at least one prior systemic anti-tumor therapy
You will not qualify if you...
- Intolerance to prior treatment with a topoisomerase I inhibitor or an antibody-drug conjugate containing this inhibitor
- Uncontrolled or clinically significant cardiovascular or cerebrovascular diseases
- Clinically significant lung diseases
- History of leptomeningeal carcinomatosis or carcinomatous meningitis
- Any illness, condition, organ dysfunction, or social situation (including mental illness or substance/alcohol abuse) that may interfere with informed consent, participation, or study result interpretation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
US-201
New Haven, Connecticut, United States, 06519
Not Yet Recruiting
2
US-202
Sarasota, Florida, United States, 34232
Actively Recruiting
3
US-204
Boston, Massachusetts, United States, 02215
Not Yet Recruiting
4
US-206
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
5
US-205
Nashville, Tennessee, United States, 37203
Actively Recruiting
6
US-203
Houston, Texas, United States, 77030
Not Yet Recruiting
7
US-207
San Antonio, Texas, United States, 78229
Not Yet Recruiting
8
AUS-101
Liverpool, New South Wales, Australia, 2170
Not Yet Recruiting
9
AUS-102
Darlinghurst, Victoria, Australia, 2010
Actively Recruiting
10
AUS-104
Fitzroy, Victoria, Australia, 3065
Not Yet Recruiting
11
AUS-103
Heidelberg, Victoria, Australia, 3084
Not Yet Recruiting
12
AUS-105
Nedlands, Western Australia, Australia, 6009
Not Yet Recruiting
13
CN-303
Harbin, Heilongjiang, China, 150081
Actively Recruiting
14
CN-301
Shanghai, Shanghai Municipality, China, 200030
Actively Recruiting
15
CN-302
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
Research Team
M
Medilink Study Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here